Search research articles
Contact Us
Filters
Showing results (71-80 of 124) with videos related to
Page
of 13
Sort By:
Blood Advances
|
June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Constantine S Tam, Stephen Opat, David Simpson, et al.
Haematologica
|
September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
Transfusion
|
January 12, 2024
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes
Allison Mo, Erica Wood, Jake Shortt, et al.
Blood
|
December 14, 2017
Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome
Stephen Opat, Anna C Hearps, Kevin Thia, et al.
Pathology
|
January 7, 2020
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group
M Gohar Maqbool, Constantine S Tam, Ian M Morison, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Vaccine
|
December 8, 2024
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Amy Body, Luxi Lal, Sriganesh Srihari, et al.
Blood Advances
|
November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
Laurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
The New England Journal of Medicine
|
October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Robert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Page
of 13
Search research articles
Search
Showing results (71-80 of 124) with videos related to
Sort By:
Page
of 13
Blood Advances
|
June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma
Constantine S Tam, Stephen Opat, David Simpson, et al.
Haematologica
|
September 28, 2023
Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
Christopher R Flowers, Matthew J Matasar, Alex F Herrera, et al.
Transfusion
|
January 12, 2024
Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes
Allison Mo, Erica Wood, Jake Shortt, et al.
Blood
|
December 14, 2017
Adaptive reprogramming of NK cells in X-linked lymphoproliferative syndrome
Stephen Opat, Anna C Hearps, Kevin Thia, et al.
Pathology
|
January 7, 2020
A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group
M Gohar Maqbool, Constantine S Tam, Ian M Morison, et al.
British Journal of Haematology
|
December 16, 2021
Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study
Gavin Cull, Jan A Burger, Stephen Opat, et al.
Vaccine
|
December 8, 2024
Comprehensive humoral and cellular immune responses to COVID-19 vaccination in adults with cancer
Amy Body, Luxi Lal, Sriganesh Srihari, et al.
Blood Advances
|
November 8, 2021
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
Laurie H Sehn, Mark Hertzberg, Stephen Opat, et al.
Blood Advances
|
January 18, 2025
Definitions and use of tumor bulk in phase 3 lymphoma trials: a comprehensive literature review
Luke Wang, Eliza Chung, Cameron Wellard, et al.
The New England Journal of Medicine
|
October 5, 2017
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Robert Marcus, Andrew Davies, Kiyoshi Ando, et al.
Page
of 13